Blood Clot Risks For Yasmin, Yaz, Ortho Evra Get Panel Review After FDA Epidemiology Study
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Reproductive Health Drugs and Drug Safety and Risk Management advisory committees will discuss the benefits and risks of drospirenone-containing drugs and the Ortho Evra patch at a two-day meeting in December.
You may also be interested in...
Zyvox Drug Interactions Draw Second Safety Communication From FDA, But Pfizer Says Info Isn't New
FDA and Pfizer appear to disagree over whether new information about harmful drug interactions between Pfizer’s antibiotic Zyvox (linezolid) and serotonergic antidepressants, including multiple deaths, led the agency to issue a drug safety communication.
Zyvox Drug Interactions Draw Second Safety Communication From FDA, But Pfizer Says Info Isn't New
FDA and Pfizer appear to disagree over whether new information about harmful drug interactions between Pfizer’s antibiotic Zyvox (linezolid) and serotonergic antidepressants, including multiple deaths, led the agency to issue a drug safety communication.
Yasmin Safety Labeling Change May Depend On FDA Epidemiologic Study
Results from the FDA-funded retrospective epidemiologic cohort study of more than 800,000 women are expected later this summer.